Unii-33Y9anm545

1. Introduction of Pazopanib Hydrochloride
Pazopanib Hydrochloride is a white crystalline powder. The IUPAC name of this chemical is called 5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide hydrochloride. This chemical's classification codes are Antineoplastic Agents; Antineoplastic agent, a potent and selective inhibitor of VEGFR-1, -2 and -3 tyrosine kinases, blocking angiogenesis. Pazopanib Hydrochloride belongs to the product categories of HFC80011. Pazopanib Hydrochloride Solubility in DMSO is ≥92mg/mL. The Pazopanib Hydrochloride is also known as Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-, monohydrochloride.

2. Properties of Pazopanib Hydrochloride
Physical properties about Pazopanib Hydrochloride are:
(1)ACD/LogP: 1.98; (2)# of Rule of 5 Violations: 0; (3)ACD/LogD (pH 5.5): 2; (4)ACD/LogD (pH 7.4): 2; (5)ACD/BCF (pH 5.5): 17; (6)ACD/BCF (pH 7.4): 19; (7)ACD/KOC (pH 5.5): 260; (8)ACD/KOC (pH 7.4): 284; (9)#H bond acceptors: 9; (10)#H bond donors: 3; (11)#Freely Rotating Bonds: 4; (12)Flash Point: 394.6 °C; (13)Enthalpy of Vaporization: 106.39 kJ/mol; (14)Boiling Point: 728.8 °C at 760 mmHg; (15)Vapour Pressure: 4.26E-21 mmHg at 25°C.

3. Structure Descriptors of Pazopanib Hydrochloride
You can still convert the following datas into molecular structure:
(1)Canonical SMILES: CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N.Cl
(2)InChI: InChI=1S/C21H23N7O2S.ClH/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16;/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25);1H
(3)InChIKey: MQHIQUBXFFAOMK-UHFFFAOYSA-N
(4)Smiles: Cc1ccc(cc1S(=O)(=O)N)Nc2nccc(n2)N(C)c3ccc4c(n(nc4c3)C)C.Cl

4. Uses of Pazopanib Hydrochloride
The hydrochloride salt of a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated. Check for active clinical trials or closed clinical trials using this agent.